Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics’ proprietary Tumor Glycoform specific scFv discovery platform and CiMaas’s Adoptive CAR-NK technology.
CiMaas has filed a new patent application on a new method for the feeder cell preparation in support of its NK cell therapy program. Treatment with Natural Killer (NK) cells is the CiMaas strategy to potentially cure patients with cancer. CiMaas uses a feeder cell based NK cell expansion protocol to generate high NK cell… Read more »
CiMaas BV announces that it has created a GMP grade master cell bank of the F012 feeder cell line to support Natural Killer (NK) cell expansion isolated from peripheral blood cells. CiMaas had generated a feeder cell line containing two genes that induce NK cell proliferation and maturation resulting in NK cells with a memory… Read more »
CiMaas’ leading product to fight cancer is Natural Killer (NK) cells. These cells kill tumor cells directly as has been observed in pre-clinical studies, as well as in clinical studies (patients with myeloid leukemia). To obtain a large number of these NK cells to treat patients, so-called feeder cells are needed to stimulate the proliferation… Read more »
By entering into a research collaboration with an option for an exclusive commercial license for its antibody structures (specific directed against underglycosylated Mucin-1 and potentially other candidates) to CiMaas, the Technical University of Denmark (DTU) and CiMaas have strengthened their relation to fight cancer.
After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas as of December 18, 2022.
CiMaas BV, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary NK cell expansion platform, announced the date for a presentation of the company at the Biotech Showcase 2023, the investor conference as follows: Monday, January 09, 2023, at 3:00PM at the Hilton San Francisco – Union Square, 333 O’Farrell… Read more »
CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral blood, NK are expanded to numbers meeting the expected clinically required 10.E8 cells/kg, with multiple infusions. This makes the expansion method developed directly applicable for clinical application of the produced NK cells in anti-cancer therapies.
As of March 1, 2022, CiMaas is a licensed manufacturer for cell-based products. The company received the manufacturing authorization from the Dutch Ministry of Health, Welfare and Sport – Farmatec/CIBG.
CiMaas, together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of € 1,48 million to further develop Natural Killer Cell therapy for breast cancer.